BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1021 related articles for article (PubMed ID: 24904965)

  • 21. Design and Synthesis of Arylnaphthalene Lignan Lactone Derivatives as Potent Topoisomerase Inhibitors.
    Chen W; Feng Z; Hu D; Meng J
    Med Chem; 2021; 17(8):856-865. PubMed ID: 32520691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular modelling design, synthesis and cytotoxic evaluation of certain substituted 2-(3,4,5-triacetoxybenzoylamino)benzo[d]thiazole and 2-(galloylamino)benzo[d]thiazole derivatives having potential topoisomerase-I inhibitory activity.
    Ismail MA; Tratrat C; Haroun MG
    J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1331-45. PubMed ID: 22957723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and synthesis of 4-amino-2-phenylquinazolines as novel topoisomerase I inhibitors with molecular modeling.
    Le TN; Yang SH; Khadka DB; Van HT; Cho SH; Kwon Y; Lee ES; Lee KT; Cho WJ
    Bioorg Med Chem; 2011 Jul; 19(14):4399-404. PubMed ID: 21684168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
    Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison.
    Karki R; Park C; Jun KY; Kadayat TM; Lee ES; Kwon Y
    Eur J Med Chem; 2015 Jan; 90():360-78. PubMed ID: 25437622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
    Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
    Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
    Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
    Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, synthesis and antitumor activity of non-camptothecin topoisomerase I inhibitors.
    Zhang C; Li S; Ji L; Liu S; Li Z; Li S; Meng X
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4693-6. PubMed ID: 26384290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
    Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
    Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents.
    Thapa P; Jun KY; Kadayat TM; Park C; Zheng Z; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
    Bioorg Med Chem; 2015 Oct; 23(19):6454-66. PubMed ID: 26361737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
    Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
    Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.
    Wambang N; Schifano-Faux N; Aillerie A; Baldeyrou B; Jacquet C; Bal-Mahieu C; Bousquet T; Pellegrini S; Ndifon PT; Meignan S; Goossens JF; Lansiaux A; Pélinski L
    Bioorg Med Chem; 2016 Feb; 24(4):651-60. PubMed ID: 26740155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4β-[4'-(1-(Aryl)ureido)benzamide]podophyllotoxins as DNA topoisomerase I and IIα inhibitors and apoptosis inducing agents.
    Kamal A; Suresh P; Ramaiah MJ; Srinivasa Reddy T; Kapavarapu RK; Rao BN; Imthiajali S; Lakshminarayan Reddy T; Pushpavalli SN; Shankaraiah N; Pal-Bhadra M
    Bioorg Med Chem; 2013 Sep; 21(17):5198-208. PubMed ID: 23849207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors.
    Zhao Q; Xu X; Xie Z; Liu X; You Q; Guo Q; Zhong Y; Li Z
    Bioorg Med Chem Lett; 2016 Feb; 26(3):1068-1072. PubMed ID: 26725027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Topoisomerase inhibitors as anticancer agents: a patent update.
    Khadka DB; Cho WJ
    Expert Opin Ther Pat; 2013 Aug; 23(8):1033-56. PubMed ID: 23611704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorinated 3,6,9-trisubstituted acridine derivatives as DNA interacting agents and topoisomerase inhibitors with A549 antiproliferative activity.
    Nunhart P; Konkoľová E; Janovec L; Jendželovský R; Vargová J; Ševc J; Matejová M; Miltáková B; Fedoročko P; Kozurkova M
    Bioorg Chem; 2020 Jan; 94():103393. PubMed ID: 31679839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as Topoisomerase I inhibitors.
    Liu W; Zhu L; Guo W; Zhuang C; Zhang Y; Sheng C; Cheng P; Yao J; Wang W; Dong G; Wang S; Miao Z; Zhang W
    Eur J Med Chem; 2011 Jun; 46(6):2408-14. PubMed ID: 21463912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.